Kura Oncology Inc. (KURA)
KURA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1422143/000119312526092567/0001193125-26-092567-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KURA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001422143 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $67.5M |
| Net income | -$278.7M |
| Operating income | -$303.6M |
| Net margin | -412.9% |
| Operating margin | -449.9% |
| Revenue growth | +25.2% |
| Cash | $149.1M |
| Total assets | $738.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $57.9M cash; operating cash flow -$21.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 91,878,694 (2026-11-06); 87,017,518 a year earlier; 74,272,111 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.4M, sold $3.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $22.8M | -$70.2M | -$54.4M | $57.9M | $9.8M | $79.3M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $20.9M | -$68.3M | -$62.5M | $70.2M | $9.8M | $77.2M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $18.3M | -$73.3M | -$85.9M | $39.1M | $9.7M | $71.6M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $17.3M | -$81.0M | $117.3M | $149.1M | $9.7M | $67.5M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $20.8M | -$74.1M | -$80.6M | $95.3M | $9.7M | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $15.3M | -$66.1M | -$28.8M | $81.9M | $9.6M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $14.1M | -$57.4M | -$71.9M | $51.3M | $9.6M | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$19.2M | $269.1M | $224.5M | $9.5M | $53.9M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-10 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-05-26 |
Source: SEC EDGAR submissions feed, 810 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.9% |
| 1 month | -21.0% |
| 3 months | -23.0% |
| Year to date | -25.2% |
| 1 year | -27.2% |
| From 52-week high | -42.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| JANX | Janux Therapeutics Inc. | $10.92 | -3.96% | $668.1M |
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier